Khanna's "Global Fairness in Drug Pricing Act" bill includes a "most favored nation," or 'international reference pricing," drug pricing provision, according to a summary provided by Khanna.

Related: Trump takes on Big Pharma with new executive order calling for U.S. to match lower prices abroad

The Khanna bill also includes antitrust and drug import provisions.

Khanna, a California Democrat, introduced the bill with a Democratic cosponsor, Rep. Marcy Kaptur, D-Ohio, and two Republicans: Reps. Andy Biggs, R-Ariz., and Anna Paulina Luna, R-Fla.

The bill is under the jurisdiction of the House Energy and Commerce, Ways and Means and Judiciary committees.

Other lawmakers have introduced similar types of bills. Other active drug price bills include the Fair Prescription Drug Prices for Americans Act bill, which was introduced by Sen. Josh Hawley, R-Mo., and includes a most-favored-nation pricing provision, and the "Affordable and Safe Prescription Drug Importation Act," which was introduced by Rep. Janice Schakowsky, D-Ill., and includes drug importation provisions.

But the Khanna bills appears to be the one that most closely resembles the executive order.

Passing the Khanna bill would be better than simply implementing Trump's order, because the order, "while a step forward, could be tied up in the courts and delayed indefinitely without action from Congress," according to Khanna's bill introduction announcement.

"Americans are getting ripped off," Khanna said in a statement about the bill. "It's deeply unfair that we're paying significantly more for the same prescription drugs than people in other countries. There is bipartisan outrage, and Congress must come together to act."

What it means: How much a most-favored-nation pricing bill would affect employers' prescription drug prices is unclear.

Margaret Kyle, an economics professor at Mines Paris-PSL, has shown in a new paper that, although prices for brand-name drugs are higher in the United States than in other, similar countries, prices for generic drugs are lower, and she has warned that pharmaceutical company manufacturers and distributors can use many strategies to block the effects of most-favored-nation pricing laws.

The process: Republican congressional leaders are unlikely to let Khanna's bill be the vehicle for implementing Trump's executive order, but it shows the subject continues to bring Democrats and Republicans together.

The bill may have too little to do with the federal budget for it to be included in the One Big Beautiful Bill, the big House tax and budget package.

House leaders could end up using debate over the Khanna bill, the Schakowsky bill, a House version of the Hawley bill and similar bills to heal the wounds created by the tax and budget package negotiations and restore some ability for Republicans and Democrats to work together.